Long-term Efficacy and Predictors of Response to Infliximab in Korean Patients with Crohn's Disease

Kang-Moon Lee

doi:10.4166/kjg.2013.61.5.241

Journal List > Korean J Gastroenterol > v.61(5) > 1007081

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee: Long-term Efficacy and Predictors of Response to Infliximab in Korean Patients with Crohn's Disease

Editorial

Korean J Gastroenterol 2013;61(5):241-242.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.61.5.241

Long-term Efficacy and Predictors of Response to Infliximab in Korean Patients with Crohn's Disease

Kang-Moon Lee

Department of Internal Medicine, St. Vincent Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea

Correspondence to: Kang-Moon Lee, Department of Internal Medicine, The Catholic University of Korea, St. Vincent Hospital, 93 Jungbu- daero, Paldal-gu, Suwon 442-723, Korea. Tel: +82-31-249-8151, Fax: +82-31-253-8898, E-mail: drmaloman@catholic.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Clinical Outcome of Treatment with Infliximab in Crohn's Disease: A Single-Center Experience (Korean J Gastroenterol 2013;61:270–278)

References

1. Cosnes J, Cattan S, Blain A, et al. Longterm evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8:244–250.

2. Solberg IC, Vatn MH, Høie O, et al. IBSEN Study Group. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5:1430–1438.

3. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121:255–260.

4. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54:237–241.

5. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther. 2011; 33:857–869.

6. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337:1029–1035.

7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541–1549.

8. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340:1398–1405.

9. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350:876–885.

10. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126:402–413.

11. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005; 128:862–869.

12. Schnitzler F, Fidder H, Ferrante M, et al. Longterm outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58:492–500.

13. Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis. 2012; 6:143–153.

14. Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf. 2011; 20:838–848.

15. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009; 15:1295–1301.

16. Baert F, Moortgat L, Van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138:463–468.

17. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362:1383–1395.

18. Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea. Korean J Gastroenterol. 2005; 46:48–55.

19. Kim SH, Yang S, Kim KJ, et al. Efficacy of infliximab in the treatment of Korean patients with Crohns disease. Korean J Gastroenterol. 2009; 54:108–116.

20. Kim YJ, Kim JW, Lee CK, et al. Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience. Korean J Gastroenterol. 2013; 61:270–278.

TOOLS

Similar articles